Form 4: Guardant Health CTO Vests Performance RSUs

Guardant Health's Chief Technology Officer, Darya Chudova, reported the vesting of performance-based restricted stock units and the subsequent disposition of shares for tax withholding.

Summary

• Darya Chudova, Chief Technology Officer of Guardant Health, Inc. (GH), reported transactions on March 15, 2026.
• Acquired 10,714 shares of Common Stock at a price of $0 due to the vesting of performance-based restricted stock units.
• Disposed of 5,759 shares of Common Stock at $85.49 per share to cover tax withholding obligations related to the RSU vesting.
• The performance-based restricted stock unit award was granted on June 7, 2023, with a 3-year performance metric, and the second tranche metric was achieved.
• Following these transactions, Chudova beneficially owns 64,352 shares of Common Stock directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as the vesting of performance-based RSUs indicates the achievement of company performance metrics, reflecting positively on the executive's contribution and the company's operational success in that specific area.

Positives

• Vesting of 10,714 performance-based restricted stock units indicates the achievement of a 3-year performance metric.
• The vesting at a $0 exercise price represents a gain for the executive.

Negatives

• 5,759 shares were disposed of at $85.49 to cover tax withholding obligations, reducing the executive's direct shareholding.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions like RSU vestings and tax-related sales are common occurrences for executives in the biotechnology and healthcare diagnostics sector, reflecting standard compensation practices and tax planning.

Stakeholder Impact

• Shareholders: The vesting of performance-based units could be seen as a positive indicator of management achieving set goals, potentially boosting confidence. The sale for tax purposes is a routine event and generally has minimal impact on overall share price or company valuation.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of performance-based restricted stock units and a subsequent sale of shares to cover tax obligations. While the achievement of performance metrics is a positive signal, the transaction itself is standard and does not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Guardant Health, GH, Darya Chudova, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Ownership, Chief Technology Officer